Literature DB >> 24673673

Procalcitonin as a marker of serious bacterial infections in febrile children younger than 3 years old.

Prashant Mahajan1, Mary Grzybowski, Xinguang Chen, Nirupama Kannikeswaran, Rachel Stanley, Bonita Singal, John Hoyle, Dominic Borgialli, Elizabeth Duffy, Nathan Kuppermann.   

Abstract

OBJECTIVES: There is no perfectly sensitive or specific test for identifying young, febrile infants and children with occult serious bacterial infections (SBIs). Studies of procalcitonin (PCT), a 116-amino-acid precursor of the hormone calcitonin, have demonstrated its potential as an acute-phase biomarker for SBI. The objective of this study was to compare performance of serum PCT with traditional screening tests for detecting SBIs in young febrile infants and children.
METHODS: This was a prospective, multicenter study on a convenience sample from May 2004 to December 2005. The study was conducted in four emergency departments (EDs): one pediatric ED and three EDs with pediatric units, all with academic faculty on staff. A total of 226 febrile children 36 months old or younger who presented to the four participating EDs and were evaluated for SBI by blood, urine, and/or cerebral spinal fluid (CSF) cultures were included.
RESULTS: The test characteristics (with 95% confidence intervals [CIs]) of the white blood cell (WBC) counts including neutrophil and band counts were compared with PCT for identifying SBI. Thirty children had SBIs (13.3%, 95% CI = 8.85 to 17.70). Four (13.3%) had bacteremia (including one with meningitis), 18 (60.0%) had urinary tract infections (UTIs), and eight (26.6%) had pneumonia. Children with SBIs had higher WBC counts (18.6 × 10(9)  ± 8.6 × 10(9) cells/L vs. 11.5 × 10(9)  ± 5.3 × 10(9) cells/L, p < 0.001), higher absolute neutrophil counts (ANCs; 10.6 × 10(9)  ± 6.7 × 10(9) cells/L vs. 5.6 × 10(9)  ± 3.8 × 10(9) cells/L, p = 0.009), higher absolute band counts (0.90 × 10(9)  ± 1.1 × 10(9) cells/L vs. 0.35 × 10(9)  ± 0.6 × 10(9) cells/L, p = 0.009), and higher PCT levels (2.9 ± 5.6 ng/mL vs. 0.4 ± 0.8 ng/mL, p = 0.021) than those without SBIs. In a multivariable logistic regression analysis, the absolute band count and PCT were the two screening tests independently associated with SBI, although the area under the receiver operating characteristic (ROC) curve for PCT was the largest (0.80, 95% CI = 0.71 to 0.89).
CONCLUSIONS: Procalcitonin is a more accurate biomarker than traditional screening tests for identifying young febrile infants and children with serious SBIs. Further study on a larger cohort of young febrile children is required to definitively determine the benefit of PCT over traditional laboratory screening tests for SBIs.
© 2014 by the Society for Academic Emergency Medicine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24673673     DOI: 10.1111/acem.12316

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  19 in total

Review 1.  Management of the Febrile Young Infant: Update for the 21st Century.

Authors:  Christopher Woll; Mark I Neuman; Paul L Aronson
Journal:  Pediatr Emerg Care       Date:  2017-11       Impact factor: 1.454

2.  Practice Variation in the Evaluation and Disposition of Febrile Infants ≤60 Days of Age.

Authors:  Alexander J Rogers; Nathan Kuppermann; Jennifer Anders; Genie Roosevelt; John D Hoyle; Richard M Ruddy; Jonathon E Bennett; Dominic A Borgialli; Peter S Dayan; Elizabeth C Powell; T Charles Casper; Octavio Ramilo; Prashant Mahajan
Journal:  J Emerg Med       Date:  2019-04-20       Impact factor: 1.484

3.  Estimating the probability of bacterial infection using a novel biomarker among pediatric patients in the emergency department.

Authors:  Michelle Eckerle; Patrick Lahni; Hector Wong
Journal:  Biomarkers       Date:  2016-05-16       Impact factor: 2.658

4.  Use of procalcitonin and C-reactive protein in the diagnosis of bacterial infection in infants with severe bronchiolitis.

Authors:  Carme Alejandre; Carmina Guitart; Mònica Balaguer; Isabel Torrús; Sara Bobillo-Perez; Francisco José Cambra; Iolanda Jordan
Journal:  Eur J Pediatr       Date:  2020-09-14       Impact factor: 3.183

5.  Accuracy of Complete Blood Cell Counts to Identify Febrile Infants 60 Days or Younger With Invasive Bacterial Infections.

Authors:  Andrea T Cruz; Prashant Mahajan; Bema K Bonsu; Jonathan E Bennett; Deborah A Levine; Elizabeth R Alpern; Lise E Nigrovic; Shireen M Atabaki; Daniel M Cohen; John M VanBuren; Octavio Ramilo; Nathan Kuppermann
Journal:  JAMA Pediatr       Date:  2017-11-06       Impact factor: 16.193

6.  Role of procalcitonin in diagnosis of community acquired pneumonia in Children.

Authors:  Vinod H Ratageri; Puspha Panigatti; Aparna Mukherjee; Rashmi R Das; Jagdish Prasad Goyal; Javeed Iqbal Bhat; Bhadresh Vyas; Rakesh Lodha; Deepak Singhal; Prawin Kumar; Kuldeep Singh; Samarendra Mahapatro; Bashir Ahmad Charoo; S K Kabra; K R Jat
Journal:  BMC Pediatr       Date:  2022-04-20       Impact factor: 2.567

7.  Clinical and Cost-Effectiveness of Procalcitonin Test for Prodromal Meningococcal Disease-A Meta-Analysis.

Authors:  Jennifer M Bell; Michael D Shields; Ashley Agus; Kathryn Dunlop; Thomas Bourke; Frank Kee; Fiona Lynn
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

8.  Impact of the lab-score on antibiotic prescription rate in children with fever without source: a randomized controlled trial.

Authors:  Laurence Lacroix; Sergio Manzano; Lynda Vandertuin; Florence Hugon; Annick Galetto-Lacour; Alain Gervaix
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

9.  The Value of the "Lab-Score" Method in Identifying Febrile Infants at Risk for Serious Bacterial Infections.

Authors:  Diana Aniela Moldovan; Maria Despina Baghiu; Alina Balas; Sorana Teodora Truta
Journal:  J Crit Care Med (Targu Mures)       Date:  2015-03-01

10.  Alterations in biochemical markers in adenovirus infection.

Authors:  Constanza Gómez de Oña; Marta E Alvarez-Argüelles; Susana Rojo-Alba; Helena Casares; Mireia Arroyo; Julián Rodríguez; María de Oña; Santiago Melón
Journal:  Transl Pediatr       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.